Navigation Links
Rafarma Pharmaceuticals, Inc. Achieves Full Certification
Date:12/18/2012

Sandy, UT (PRWEB) December 17, 2012

Rafarma Pharmaceuticals, Inc. (the ”Company”) OTC symbol “APKND” announced that its manufacturing and packaging facility in Lipetsk, Russia was fully licensed last November 9th and exhibited by GMP (“Good Manufacturing Practices”) Certificate # 109489 7000-430 (see: http://rafarma.com).

The facility is ISO 9001 and IHC Q 10 compliant. These internationally recognized certifications allow sales and distribution of all permitted products throughout Europe and all nations that are a party to the above standards. The manufacturing facility is currently operating at 30% capacity during its “start-up” phase, and is expected to reach full production during the second quarter of 2013.

With the resignation of Vladimir Bondar as Director and President and Natalia Leonidovna Stupina as Director and CFO due to other commitments, the Company appointed Mr. Sergey Brusnitsin as its new Director and CFO. Mr. Brusnitsin earned his PhD in Economics from the Moscow Institute of Economics and was formerly the director of the Federal Revenue Service of Russia. He has been affiliated with the Company in several capacities throughout its development phase. Mr. Alexander Ageev continues to function as Director, Secretary/Treasurer and Mr. David Anderson will remain as Director and CEO and perform the function of President until the first annual meeting, now scheduled for March 1, 2013.

With expended development costs in excess of $200 million, and expected first year revenue expectations exceeding $100 million, and an excellent product portfolio, the Company is expected to be a leading supplier of pharmaceuticals in the years to come.

The new OTC trading symbol for the Company will be announced by FINRA on January 2, 2013 and be effective January 3, 2013.

Safe Harbor Statement
Matters discussed in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. When used in this press release, the words "anticipate," "believe," "estimate," "may," "intend," "expect" and similar expressions identify such forward-looking statements. Actual results, performance or achievements could differ materially from those contemplated, expressed or implied by the forward-looking statements contained herein. These forward-looking statements are based largely on the expectations of the Company and are subject to a number of risks and uncertainties. These include, but are not limited to: the impact of economic, competitive and other factors affecting the Company and its operations, markets, product, and distributor performance.

Media Contact: Dave Anderson, +1 801 210 7135, info (at) rafarma (dot) com

Rafarma Pharmaceuticals, Inc., http://www.rafarma.com
SOURCE: Rafarma Pharmaceuticals, Inc.

Read the full story at http://www.prweb.com/releases/2012/12/prweb10246154.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Auxilium Pharmaceuticals, Inc. to Present At The Oppenheimer 23rd Annual Growth Conference
2. Ampio Pharmaceuticals, Inc. (AMPE) announces appointment of Josh Disbrow as Chief Operating Officer effective December 15, 2012
3. OncoGenex Pharmaceuticals, Inc. Provides Clinical Development Update and Reports Financial Results for Third Quarter 2012
4. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2012 Financial Results
5. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess of $100,000 Investing In Keryx Biopharmaceuticals, Inc. To Contact the Firm
6. FierceBiotech Names Enanta Pharmaceuticals, Inc. a Fierce 15 Winner
7. Auxilium Pharmaceuticals, Inc. to Present at the Canaccord Genuity 32nd Annual Growth Conference
8. MAP Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
9. Auxilium Pharmaceuticals, Inc. to Present At The JMP Securities 2012 Healthcare Conference
10. Auxilium Pharmaceuticals, Inc. to Present at the Jefferies 2012 Global Healthcare Conference
11. Silence Therapeutics Partner, Quark Pharmaceuticals, Extends its Agreement With Pfizer to Develop one of Its Compounds Containing Silences AtuRNAi in a New Indication
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... ... January 17, 2017 , ... NeoTrident, a leading provider of ... performance management systems for high-consequence industries, announced today that they have entered into ... industry, organizations must pay much more attention to the quality of products than ...
(Date:1/16/2017)... 16, 2017   Valentin A. Pavlov, PhD , ... president and CEO of The Feinstein Institute for ... of how the nervous system regulates the immune system, ... bioelectronic medicine devices to treat disease and injury. ... . The paper examines various studies which ...
(Date:1/13/2017)... Research and Markets has announced the addition ... Forecast to 2021" report to their offering. ... The biosimilars market is expected ... in 2016, at a CAGR of 26.3%. The ... type, and application. Factors such as rising incidence of various diseases, ...
(Date:1/12/2017)... ... January 12, 2017 , ... ... SUCCESS , VTI, Vertebral Technologies, Inc., announces the successful outcome of the ... Since September 2016, VTI (Vertebral Technologies, Inc.) has partnered with Mexico-based medical ...
Breaking Biology Technology:
(Date:12/20/2016)... and GENEVA, Dec, 20, 2016   Valencell , ... technology, and STMicroelectronics (NYSE: STM), a global ... electronics applications, announced today the launch of a ... biometric wearables that includes ST,s compact SensorTile ... Benchmark™ biometric sensor system. Together, SensorTile and ...
(Date:12/16/2016)... global wearable medical device market, in terms of value, is projected ... in 2016, at a CAGR of 18.0% during the forecast period. ... Growth in ... launch of a growing number of smartphone-based healthcare apps compatible with ... increasing focus on physical fitness. Furthermore, growing trend ...
(Date:12/15/2016)... 15, 2016 Advancements in biometrics ... wellness and wellbeing (HWW), and security of ... new passenger vehicles begin to feature fingerprint ... heart beat monitoring, brain wave monitoring, stress ... and pulse detection. These will be driven ...
Breaking Biology News(10 mins):